Daré Bioscience Advances Sildenafil Cream to Phase 3 Study

Daré Bioscience ( (DARE) ) has issued an update.

Daré Bioscience announced plans for a Phase 3 clinical study of Sildenafil Cream, an investigational treatment for female sexual arousal disorder (FSAD) in premenopausal women. The study, reflecting FDA feedback, aims to address a significant unmet need in women’s sexual health by potentially becoming the first FDA-approved pharmacological treatment for FSAD, thus creating a new market category within female sexual dysfunction.

More about Daré Bioscience

Daré Bioscience is a biopharmaceutical company focused on developing innovative products for women’s health, with a mission to expand treatment options and improve outcomes in areas such as contraception, sexual health, pelvic pain, fertility, infectious diseases, and menopause.

YTD Price Performance: -39.46%

Average Trading Volume: 47,392

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $27.67M

For detailed information about DARE stock, go to TipRanks’ Stock Analysis page.